Imaging biomarkers in prostate cancer: role of PET/CT and MRI

M. Picchio, P. Mapelli, V. Panebianco, P. Castellucci, E. Incerti, A. Briganti, G. Gandaglia, M. Kirienko, F. Barchetti, C. Nanni, F. Montorsi, L. Gianolli, S. Fanti

Research output: Contribution to journalArticlepeer-review


Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate cancer (PCa). PSA suggests the presence of primary tumour and disease relapse after treatment, but it is not able to provide a clear distinction between locoregional and distant disease. Molecular and functional imaging, that are able to provide a detailed and comprehensive overview of PCa extension, are more reliable tools for primary tumour detection and disease extension assessment both in staging and restaging. In the present review we evaluate the role of PET/CT and MRI in the diagnosis, staging and restaging of PCa, and the use of these imaging modalities in prognosis, treatment planning and response assessment. Innovative imaging strategies including new radiotracers and hybrid scanners such as PET/MRI are also discussed.

Original languageEnglish
Pages (from-to)644-655
Number of pages12
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number4
Publication statusPublished - 2015


  • Biomarker
  • Imaging
  • MRI
  • PET/CT
  • Prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)


Dive into the research topics of 'Imaging biomarkers in prostate cancer: role of PET/CT and MRI'. Together they form a unique fingerprint.

Cite this